{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IPX",
  "name": "IperionX Limited",
  "url": "https://frontierpicks.com/dossiers/IPX/",
  "json_url": "https://frontierpicks.com/dossiers/IPX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue, below all moving averages, with an open securities probe — a downtrend that capitulated into its own discounted raise. The setup does not clear until it bases and reclaims the low-$30s on volume.",
  "invalidation_trigger": "A weekly close below $21.66 loses the 52-week low and the July $21.98 raise floor, confirming the sovereignty bid has exited; secondarily, escalation of the open securities probe to a filed class action, or a second discounted equity raise.",
  "catalyst_date": "2026-08-31",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-06-16",
  "invalidation_fired": true,
  "themes": [
    "critical-materials-rare-earths",
    "defense-aerospace",
    "cyclical-industrials"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Dual-listed on ASX (IPX.AX); the Nasdaq ADS represents 10 ordinary shares, so US sessions open to overnight Australian moves.",
    "Pre-revenue: the 2026-07-30 June quarterly disclosed no customer revenue. Reporting cadence is the ASX quarterly cash report, not a US-style earnings call.",
    "Securities investigations open since March 2026 (Glancy Prongay, Holzer & Holzer, Frank R. Cruz) over the right-of-use restatement; still investigation stage, no class action filed as of 2026-08-23.",
    "Proposed Texas redomiciliation would replace the ADS structure with direct Nasdaq common stock; subject to shareholder and court approval, no timetable published as of 2026-08-23.",
    "Titan's US$381.3M development capex is not covered by the ~US$84M pro-forma cash; project financing remains a separate future event.",
    "US$37.1M of obligated reimbursable U.S. Government funding remained undrawn against the DPA Title III framework as of the June 2026 quarterly."
  ],
  "body_markdown": "## Current Thesis\nThe leg that carried IperionX to $60.11 — domestic titanium metal re-rated on critical-minerals sovereignty flow — is not the leg on offer today. The 2026-07-08 placement of 2,275,000 ADS at $21.98, roughly 22% under the ~$28 pre-deal level, showed where the marginal institutional bid actually sat, and price has not travelled far from it since: a close of $22.50 on 2026-08-21, six weeks inside a rough $22–24 range, 62.6% below the 52-week high and 40.2% lower over three months, with RSI(14) at 53.6. What an investor buys here is a corporate restructuring idea plus an unproven operational ramp. The corporate part is the 2026-08-03 proposal to redomicile under a Texas-incorporated ultimate parent whose common stock would list directly on Nasdaq, retiring the ADS line — announced with no shareholder-meeting date, no court date and no scheme booklet, and still undated as of 2026-08-23. The tape has since gone silent — StockTitan's news index shows no company release between the 2026-08-05 investor webinar and 2026-08-23. The FY26 Appendix 4E, due under ASX Listing Rule 4.3A within two months of the 30 June balance date, is the first event that can put a full-year number against any of it.\n\n## Bull Case\n- **A structural discount gets a named remedy, 2026-08-03.** A newly incorporated Texas parent would become the group's ultimate parent, with Nasdaq-listed common stock replacing the ADS structure, subject to shareholder, court, regulatory and exchange approvals. StockTitan recorded a +3.95% close that session after a +10.7% intraday peak — the largest single-headline response since the July raise.\n- **Near-term funding pressure is answered, 2026-07-30 quarterly.** Cash US$35.2M at 2026-06-30; pro-forma ~US$84M including the US$50M ADS offering and a US$2.4M DPA reimbursement received after quarter-end.\n- **Government money is contracted, not aspirational.** The June quarterly disclosed US$37.1M of remaining obligated reimbursable U.S. Government funding within the DPA Title III framework against the US$12.7M award, with US$2.4M reimbursed post-quarter.\n- **Titan DFS economics, 2026-06-04:** US$813M after-tax NPV8, 39.4% IRR, US$381.3M development capex, 3.6-year payback, with a Dy/Tb/Y heavy-rare-earth concentrate in the same flowsheet.\n- **Board matched to the corporate plan, effective 2026-08-03:** Michael J. Loparco appointed independent non-executive director, an advanced-manufacturing and global supply-chain executive.\n- **Published sell-side has not marked down.** Aggregator consensus in August 2026 shows 5 Buy / 0 Sell across six analysts, a median target near $53 inside a $40–$71 range, against the $23.57 close of 2026-08-14. No covering broker has been observed cutting below the $40 bottom of that range.\n\n## Bear Case\n- **Still no revenue line.** The 2026-07-30 June quarterly describes prototype production, product development, qualification testing and low-rate initial production across defense, aerospace, automotive, consumer electronics and industrial customers, and discloses no customer revenue figure for the quarter.\n- **The ramp hit a physical constraint.** Virginia HAMR operations ran 24/7 but output was temporarily reduced by furnace downtime during the June quarter, against the ~200 tpa end-CY2026 target.\n- **Cash landed under the prior guide.** US$35.2M at 2026-06-30 versus the US$36–40M range previously indicated.\n- The 2026-08-21 close of $22.50 sits between that print and the $21.66 52-week low — the raise has not been left behind.\n- **Titan is unfunded.** US$381.3M of development capex sits against ~US$84M pro-forma cash, so project financing is a separate levered-or-dilutive event well ahead of 1,400 tpa titanium metal in mid-2027+.\n- **The restructuring is an intention, not a schedule.** Twenty days after the 2026-08-03 release there is no scheme booklet, no notice of meeting and no published Nasdaq listing date.\n- **Securities investigations remain open.** Law-firm investigation notices over the right-of-use restatement (Glancy Prongay, Holzer & Holzer, Frank R. Cruz) have been outstanding since March 2026 with no filed complaint and no resolution disclosed.\n- **Flow has thinned.** No company release from 2026-08-05 to 2026-08-23; the last dated headline response was three weeks ago.\n\n## Setup & Price Structure\nReference close 2026-08-21: $22.50. The 52-week high is $60.11, leaving the shares 62.6% below it, with a three-month price change of -40.2% and RSI(14) at 53.6 — mid-range, neither washed out nor extended. Kalkine reported the ASX line IPX.AX at A$3.06, down 6.55%, on 2026-08-19, so weakness is being set overnight in Australia and imported into US sessions rather than originated on Nasdaq.\n\nThe structure is a floor test, not a base. Two levels sit immediately underneath: the $21.98 July placement price, at which US$50M of new stock was absorbed, and the $21.66 52-week low. Price has spent six weeks between roughly $22 and $24 without approaching the low-$30s shelf that the stock lost on the way down. A range that holds under repeated tests eventually becomes a base; one that has produced no upside expansion on its only fresh headline (2026-08-03) has not yet done so.\n\nThe narrative is **dead** for the leg that ran to $60.11. What dates it — a 40.2% three-month decline, a July equity raise cleared only at a ~22% discount, a 52-week low printed at $21.66 in July, and no reclaim of the low-$30s in the seven weeks since. The redomiciliation is an attempt to start a second leg; a +3.95% close on 2026-08-03 that faded from a +10.7% intraday high, followed by 18 days of silence, is not yet evidence that one has started.\n\nCrowding and positioning observables, stated as observed: the shares trade far below every reference from the prior advance rather than extended above a rising average, so there is no distance-above-trend crowding signal here. The published analyst cluster is the one crowded object — 5 Buy / 0 Sell, median near $53 against a $22.50 close — coverage that has not been revised down and therefore carries downgrade risk rather than support. Supply was issued into weakness, not strength: the July placement was priced below market, and roughly 7% dilution was added at the lows. There is no imminent US-style earnings call; the reporting cadence is the ASX Appendix 4E and quarterly 4C. Retail-sentiment clustering shows up mainly as law-firm investigation notices dating to March 2026, not as fresh promotional coverage. Insider transaction data for the period is not in hand and is not asserted.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-31 (est.)** — FY26 preliminary final report (ASX Appendix 4E), due within two months of the 30 June year-end under ASX Listing Rule 4.3A. First full-year statements after the Titan DFS and the July raise; resolves whether any FY26 revenue is recognised and what full-year operating outflow looks like against ~US$84M pro-forma cash.\n- **~2026-09-30 (est.)** — FY26 annual report under the ASX three-month lodgement rule (just outside the 30-day window). The natural venue for a redomiciliation timetable, restatement-related disclosure and audited commentary on the right-of-use correction behind the March 2026 investigations.\n- **~2026-10-27 (est.)** — September-quarter Appendix 4C cash report (March quarter landed 2026-04-27, June quarter 2026-07-30). First quarterly that can show recovery from furnace downtime toward the ~200 tpa end-CY2026 run-rate, and any first customer receipts.\n\n## Elapsed catalysts\n\n- **Not yet dated as of 2026-08-23** — scheme booklet / notice of meeting setting a shareholder-vote date for the Texas redomiciliation. Until one is lodged the corporate leg has no gradeable date attached to it. *(passed 3d ago)*\n\n## What Would Change Our Mind\nThe structure that has to hold is the July placement shelf. US$50M of stock was cleared at $21.98 and the 52-week low sits at $21.66; losing both on a weekly close below $21.66 would say the buyers who took the discounted paper are underwater and no sovereignty bid replaced them, at which point the six-week $22–24 range reads as distribution rather than accumulation. Two secondary conditions carry the same weight: a second discounted equity raise, convertible or at-the-market program priced at or under the July level, which would confirm that ~US$84M pro-forma cash cannot carry the company to first revenue; and the FY26 Appendix 4E around 2026-08-31 arriving with no customer revenue recognised for the full year and no restated timetable for the ~200 tpa run-rate.\n\nThe reverse case is equally specific. A shareholder-meeting date and scheme booklet for the Texas parent, a first disclosed customer revenue figure in the 4E or the September 4C, or a sustained reclaim of the low-$30s on expanding volume would each mark the second leg actually beginning. Absent those, the name is a pre-revenue developer whose last funding event was priced at a discount, and the case for a fresh commitment at $22.50 is weak.\n\n## Correlation Notes\n- **Dual listing drives the open.** IPX.AX on the ASX sets price overnight; the Nasdaq ADS represents 10 ordinary shares, so US sessions inherit Australian moves — the reported -6.55% ASX session on 2026-08-19 is the mechanism, not a US-originated sell.\n- **Policy beta, not commodity beta.** The revenue case rests on DPA Title III reimbursements and US defense/aerospace qualification schedules, so the name tracks US critical-minerals policy headlines and defense appropriations more closely than any spot titanium quote.\n- **Critical-minerals complex.** Moves with the US rare-earth and strategic-metals cohort on sovereignty headlines; the Titan DFS Dy/Tb/Y concentrate adds direct rare-earth sensitivity alongside titanium.\n- **AUD/USD is an embedded cross.** Costs and the primary listing are Australian while the growth capex and customers are US-dollar, so the ADS price carries an FX leg independent of company news.\n- **Small-cap pre-revenue funding conditions.** With US$381.3M of Titan capex unfunded, the name is levered to the equity-issuance window for development-stage industrials; a shut window matters more here than the titanium price.",
  "first_seen": "2026-05-27",
  "last_analyzed": "2026-08-23T13:16:30+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}